Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 269745, 5 pages
Research Article

A Pilot Study on Intravesical Administration of Curcumin for Cystitis Glandularis

1Department of Pharmacy, Second Xiangya Hospital of Central South University, Changsha 410011, China
2Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan 614-735, Republic of Korea
3Department of Urology, Second Xiangya Hospital of Central South University, No. 139 Renminzhonglu-Road, Furong-District, Changsha 410011, China

Received 1 January 2013; Revised 20 March 2013; Accepted 9 April 2013

Academic Editor: Alfredo Vannacci

Copyright © 2013 Qiong Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cystitis glandularis (CG) is a proliferative disorder in the urinary bladder. The outcome of current treatments in some patients is not satisfactory. Curcumin, a herbal medicine that has been used for centuries, has shown great potential in treating various diseases. Our pilot study aimed to explore the feasibility of an intravesical treatment for CG using curcumin. 14 patients diagnosed with CG that remained symptomatic after primary treatments were enrolled, underwent a 3-month curcumin intravesical treatment (50 mg/50 mL, 1 hour, once per week for first 4 weeks and once per month for next 2 months) and were followed up for 3 months. Efficacy of the treatment was evaluated using core lower urinary tract symptom score (CLSS) questionnaire. 10 patients demonstrated persistent improvement in symptoms up to the end of the 6-month study. Their CLSS decreased significantly after the 3-month treatment ( ; ) from the baseline ( ) and maintained decreasing till the end of the study ( ; ). 4 patients were classified as nonresponders. Our study suggests the feasibility of further randomized controlled trials on curcumin intravesical treatment in CG patients who remain symptomatic after primary treatments.